COMMUNIQUÉS West-GlobeNewswire

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
23/12/2025
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose, [...]
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
23/12/2025
BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology [...]
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
23/12/2025
Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory Disease CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company [...]
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
23/12/2025
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by [...]
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
23/12/2025
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Top- [...]
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-Year NEW [...]
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
23/12/2025
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and Evidence Gaps Explained New York, Dec. 22, 2025 ( [...]
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025
Wegovy ® pill showed a mean weight loss of 16.6% in the OASIS 4 trial 1 Wegovy ® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse [...]
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Apollomics Reports First Half 2025 Financial Results
22/12/2025
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The [...]
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
22/12/2025
FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/12/2025
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on [...]
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
22/12/2025
Approvals expand Amneal’s biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“ [...]
Celularity Announces Closing of Financing Transactions
22/12/2025
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the [...]
Alvotech’s Financial Calendar for 2026
22/12/2025
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the [...]
Vystar® Reports, Following its First of its Kind Court Victory against EMA Financial, Inc. of $497,439.58 in Legal Fees and Costs Awarded.
22/12/2025
Worcester, MA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar ® is proud to report; Following its first of its kind court victory on behalf of Vystar Corp. (“Vystar”) against EMA Financial, [...]
Vivos Inc Summarizes Progress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
22/12/2025
WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 [...]

Pages